ImmunoScape

📍 Singapore, Singapore🗓 Founded 2016👥 37 employees💰 Last funded Dec 2019
Biotechnology Research🌐 immunoscape.com
Website LinkedIn
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The companys proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in ImmunoScape?
ImmunoScape has 1 investors on record on gritt.io, 1 mid-stage.
When did ImmunoScape last raise funding?
The most recent investment in ImmunoScape recorded on gritt.io was in December 2019.
When was ImmunoScape founded?
ImmunoScape was founded in 2016.
What industry is ImmunoScape in?
ImmunoScape operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is ImmunoScape based?
ImmunoScape is headquartered in Singapore, Singapore.